Description

Simple

A cancer medication used to treat some types of bladder cancer that have not responded well to other types of treatment.

Clinical

An anthracycline used intravesically in the treatment of BCG-resistant bladder carcinoma.

Overview

Valrubicin (N-trifluoroacetyladriamycin-14-valerate) is a chemotherapy drug commonly marketed under the trade name VALSTAR. It is a semisynthetic analog of the [doxorubicin], which is an anthracycline drug. Used in the treatment of the bladder cancer, valrubicin is administered by direct infusion into the bladder.

Pharmacology

Indication

For the treatment of cancer of the bladder.

Pharmacodynamic

Valrubicin is an anticancer agent.

Mechanism of action

Valrubicin is an anthracycline that affects a variety of inter-related biological functions, most of which involve nucleic acid metabolism. It readily penetrates into cells, where after DNA intercalation, it inhibits the incorporation of nucleosides into nucleic acids, causes extensive chromosomal d... Read more

Absorption

Information currently not available.

Protein binding

>99%

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

The primary anticipated complications of overdosage associated with intravesical administration would be consistent with irritable bladder symptoms. Myelosuppression is possible if valrubicin is inadvertently administered systemically or if significant systemic exposure occurs following intravesical... Read more

Adverse Effects

Contraindications

  • Route:
    • Intravesical
  • Dose Form:
    • Solution
  • Hypersensitivity:
    • Anthracyclines
  • Regions: US
  • Route:
    • Intravesical
  • Dose Form:
    • Solution
  • Regions: US
  • Patient Conditions:
      • Name: Small bladder capacity
      • Drugbank Id: DBCOND0107695
      • Name: Intolerance to 75 mL instillation
      • Drugbank Id: DBCOND0107696
  • Route:
    • Intravesical
  • Dose Form:
    • Solution
  • Regions: US
  • Patient Conditions:
      • Name: Perforated bladder
      • Drugbank Id: DBCOND0107693
  • Route:
    • Intravesical
  • Dose Form:
    • Solution
  • Regions: US
  • Patient Conditions:
      • Name: Active urinary tract infection
      • Drugbank Id: DBCOND0107694
      • Modification Of:
        • Condition Status: active
        • Base:
          • Name: Urinary Tract Infection
          • Drugbank Id: DBCOND0024122

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Valrubicin
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Darbepoetin alfa
The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Valrubicin.
Erythropoietin
The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Valrubicin.
Methoxy polyethylene glycol-epoetin beta
The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Valrubicin.
Peginesatide
The risk or severity of Thrombosis can be increased when Peginesatide is combined with Valrubicin.